mortality/aging
• only 10% of LPS-treated mice die compared with 80% of similarly treated wild-type mice
|
immune system
• LPS-treated mice exhibit lower serum IL6 concentration compared with similarly treated wild-type mice
|
• LPS-treated mice exhibit lower serum TNF-alpha concentration compared with similarly treated wild-type mice
|
• LPS-treated mice exhibit lower serum CXCL1 (KC) concentration compared with similarly treated wild-type mice
• LPS- or R848-treated macrophages produce less chemokine (CXCL1) compared with similarly treated wild-type cells
|
• LPS- or R848-treated macrophages produce less cytokines IL6 compared with similarly treated wild-type cells
|
• LPS- or R848-treated macrophages produce less TNF-alpha compared with similarly treated wild-type cells
|
• only 10% of LPS-treated mice die compared with 80% of similarly treated wild-type mice
• LPS-treated mice exhibit lower serum cytokine (IL6 and TNF-alpha) and chemokine concentrations compared with similarly treated wild-type mice
• LPS- or R848-treated macrophages produce less cytokines (IL6 and TNF-alpha) and chemokine (CXCL1) compared with similarly treated wild-type cells
|
homeostasis/metabolism
• LPS-treated mice exhibit lower serum IL6 concentration compared with similarly treated wild-type mice
|
• LPS-treated mice exhibit lower serum TNF-alpha concentration compared with similarly treated wild-type mice
|
• LPS-treated mice exhibit lower serum CXCL1 (KC) concentration compared with similarly treated wild-type mice
• LPS- or R848-treated macrophages produce less chemokine (CXCL1) compared with similarly treated wild-type cells
|